Daijiworld Media Network - Bengaluru
Bengaluru, May 22: Healthcare Global Enterprises Ltd. (HCG) is stepping up investments in precision medicine, molecular diagnostics, genomics and robotics as the cancer hospital chain prepares for rising demand for specialised oncology care and personalised treatment in India.
The Bengaluru-based company said it raised Rs 425 cr during FY26 through a rights issue and plans to utilise the funds for capacity expansion, clinical infrastructure upgrades, technology investments and selective growth opportunities across its network.
HCG, which operates 25 hospitals across India and Africa, said cancer care is increasingly shifting towards early diagnosis, targeted therapies and integrated treatment pathways. The company noted that technologies such as genomics and molecular diagnostics are expected to play a larger role in treatment planning and improving patient outcomes in the coming years.
Founder and Non-Executive Chairman B S Ajaikumar said cancer care today goes beyond treatment alone.
“Cancer care is no longer only about treatment. It is about early diagnosis, precision, continuity of care, and improving quality of life for patients and families,” he said. “As we look ahead, our focus is on strengthening next-generation oncology capabilities across precision medicine, molecular diagnostics, genomics, robotics and data-driven clinical decision-making.”
The company said demand remained strong across medical, radiation and surgical oncology during FY26, supported by improving patient throughput and better utilisation across centres. HCG added that its integrated care model, including tumour-board-led clinical decision-making where specialists jointly review treatment options, continues to remain central to its strategy.
Chief Executive Officer Manish Mattoo said the successful completion of the rights issue had strengthened the company’s financial position and enhanced its flexibility to invest in long-term priorities.
“A key milestone during the year was the successful completion of our Rs 425 cr rights issue, which further strengthened our financial foundation and gives us greater flexibility to invest behind our long-term priorities, including capacity expansion, clinical infrastructure upgrades, technology investments and selective growth opportunities,” he said.
Mattoo added that the company would continue focusing on improving utilisation across hospitals while selectively expanding its network.
For FY26, HCG reported consolidated revenue from operations of Rs 2,545 cr, registering a 15 per cent year-on-year growth. Adjusted EBITDA rose 19 per cent to Rs 471 cr, while the adjusted EBITDA margin improved to 18.5 per cent from 17.8 per cent in FY25.